1.
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controll...
by Baigent, Colin, Prof
The Lancet (British edition), 2011, Vol.377 (9784), p.2181-2192
2.
Proteinuria and progression of pediatric chronic kidney disease: lessons from recent clinical studies
by Fathallah-Shaykh, Sahar A
Pediatric nephrology (Berlin, West), 2016-06-27, Vol.32 (5), p.743-751
3.
A Review of Ferric Pyrophosphate Citrate (Triferic) Use in Hemodialysis Patients
by Albright, Tyler, PharmD
Clinical therapeutics, 2016, Vol.38 (10), p.2318-2323
4.
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
by Levin, Adeera, Dr
The Lancet (British edition), 2017-10-21, Vol.390 (10105), p.1888-1917
5.
SHARP: a stab in the right direction in chronic kidney disease
by Stevens, Kathryn K
The Lancet (British edition), 2011, Vol.377 (9784), p.2153-2154
6.
Prevalence of Pre-End-Stage Renal Disease Care and Associated Outcomes among Urban, Micropolitan, and Rural Dialysis Patients
by Maripuri, Saugar
American journal of nephrology, 2013-04, Vol.37 (3), p.274-280
7.
Hereditary causes of kidney stones and chronic kidney disease
by Edvardsson, Vidar O
Pediatric nephrology (Berlin, West), 2013-01-20, Vol.28 (10), p.1923-1942
8.
Gut microbiome and kidney disease: a bidirectional relationship
by Al Khodor, Souhaila
Pediatric Nephrology, 2016-04-29, Vol.32 (6), p.921-931
9.
Serum Sclerostin and Adverse Outcomes in Nondialyzed Chronic Kidney Disease Patients
by Kanbay, Mehmet
The journal of clinical endocrinology and metabolism, 2014-10, Vol.99 (10), p.E1854-E1861
10.
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study...
by Roth, David, Dr
The Lancet (British edition), 2015, Vol.386 (10003), p.1537-1545
11.
Hypertension in Chronic Kidney Disease Part 1: Out-of-Office Blood Pressure Monitoring: Methods, Thresholds, and Patterns
by Parati, Gianfranco
Hypertension (Dallas, Tex. 1979), 2016, Vol.67 (6), p.1093-1101
12.
Circulating Klotho Associates With Cardiovascular Morbidity and Mortality During Hemodialysis
by Marçais, Christophe
The journal of clinical endocrinology and metabolism, 2017-09, Vol.102 (9), p.3154-3161
13.
Pursuing minimally disruptive medicine: disruption from illness and health care-related demands is correlated with patient capacity
by Boehmer, Kasey R
Journal of clinical epidemiology, 2016, Vol.74, p.227-236
14.
Anxiety, depression, resilience and quality of life in children and adolescents with pre-dialysis chronic kidney disease
by Moreira, Janaina Matos
Pediatric nephrology (Berlin, West), 2015-07-27, Vol.30 (12), p.2153-2162
15.
Infants with congenital nephrotic syndrome have comparable outcomes to infants with other renal diseases
by Dufek, Stephanie
Pediatric nephrology (Berlin, West), 2018-10-29, Vol.34 (4), p.649-655
16.
Smaller circuits for smaller patients: improving renal support therapy with Aquadex
by Askenazi, David
Pediatric nephrology (Berlin, West), 2015-11-16, Vol.31 (5), p.853-860
17.
Peritubular capillary rarefaction: a new therapeutic target in chronic kidney disease
by Kida, Yujiro
Pediatric nephrology (Berlin, West), 2013-03-10, Vol.29 (3), p.333-342
18.
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
by Heerspink, Hiddo J. L
Diabetologia, 2019-07, Vol.62 (7), p.1154-1166
19.
Uric acid and progression of chronic kidney disease
by Weaver, Donald J
Pediatric nephrology (Berlin, West), 2018-06-21, Vol.34 (5), p.801-809
20.
Increased indoleamine 2,3-dioxygenase activity in type 2 diabetic nephropathy
by Zhang, Yue
Journal of diabetes and its complications, 2016, Vol.31 (1), p.223-227
